Great Lakes Clinical Trials' own Steve Satek was quoted today in the Chicago Defender article about the Global Alzheimer’s Platform Foundation’s breakthrough Biohermes Study.
Local Researchers Help Black & Brown Communities Detect Factors for Alzheimer’s
Local Researchers Help Black & Brown Communities Detect Factors for Alzheimer’s Chicago’s Great Lakes Clinical Trials is now enrolling volunteers with and without memory concerns in the Global Alzheimer’s Platform Foundation’s Bio-Hermes Study. The study seeks to evaluate how blood or digital biomarker tests could best help predict the presence of amyloid plaques in the brain, a hallmark of Alzheimer’s disease.
The Global Alzheimer’s Platform Foundation’s focus is to make Alzheimer’s testing and resources accessible and accurate for every population, inclusive of the African-American community. Black people are 2-3 times more likely to receive an Alzheimer’s diagnosis, but this population is severely underrepresented in clinical research. Thus, the Bio-Hermes Study has committed to enrolling at least 20% Black and LatinX volunteers, nearly 4 times the national average in Alzheimer’s research. “We are committed to diversity in our recruitment because the science demands we consider the effectiveness of biomarker tests on various populations. We know that Alzheimer’s kills slowly and impacts every racial group but takes a particular toll on African Americans,” said John Dwyer, President of the Global Alzheimer’s Platform Foundation.
Read the full article here or click the button below.